Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Artiva Biotherapeutics (NASDAQ:ARTV) from a sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other analysts also recently issued reports on ARTV. HC Wainwright boosted their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.33.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $10.89 on Friday. The company has a market capitalization of $269.20 million, a price-to-earnings ratio of -3.08 and a beta of 2.86. The company has a 50-day simple moving average of $7.59 and a 200 day simple moving average of $5.35. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Sell-side analysts forecast that Artiva Biotherapeutics will post -3.33 EPS for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ARTV. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at approximately $79,000. Qube Research & Technologies Ltd acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at approximately $58,000. Jane Street Group LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at approximately $67,000. Bridgeway Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $53,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares during the period.

Key Stories Impacting Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva reported positive initial data for AlloNK across multiple autoimmune diseases, including a 71% ACR50 response in refractory rheumatoid arthritis patients, and said the FDA agreed to a single Phase 3 registrational trial design for AlloNK plus rituximab in refractory RA. Article Title
• Positive Sentiment: Management highlighted that the Phase 3 trial could begin in the second half of 2026, with a meaningful market opportunity in heavily pretreated rheumatoid arthritis patients, supporting the long-term bull case. Article Title
• Neutral Sentiment: Artiva also reported first-quarter 2026 results and outlined recent business progress, reinforcing investor focus on the company’s pipeline and upcoming clinical milestones. Article Title
• Neutral Sentiment: The company’s quarterly loss was slightly worse than expected, but the earnings miss was not the main market-moving catalyst compared with the clinical updates and financing news. Article Title
• Negative Sentiment: Artiva priced a $300 million stock and pre-funded warrant offering, which likely pressured the shares because it increases dilution even as it strengthens the balance sheet. Article Title
• Negative Sentiment: Investor enthusiasm for the strong data appeared to be tempered by concern that the financing may offset some of the upside from the trial progress. Article Title

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.